May 16th 2012
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate
Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma
Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects
Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.
Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL
Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.
Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting
March 26th 2012
OncLive.com will be on-site at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 8th 2011
American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow
June 7th 2011
Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.
Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.
Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.
Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer
American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four
Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib
June 6th 2011
Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate
Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer
New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted
3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival
